← Back to guidelines
Pharmacology1 paper

Syphilitic leukoderma

Last edited: 4/16/2026

Overview

Syphilitic leukoderma, also known as pinecone-like leukoderma, is a rare dermatological manifestation associated with tertiary syphilis, characterized by depigmented patches resembling vitiligo. 1

Diagnosis

  • Clinical Presentation: Depigmented macules or patches, often symmetrically distributed.
  • History and Physical Examination: Detailed history of syphilis exposure and physical examination focusing on skin lesions.
  • Laboratory Tests: Serological tests for syphilis (VDRL, RPR, TPPA, FTA-ABS) 1.
  • Differential Diagnosis: Exclude other causes of depigmentation such as vitiligo, idiopathic guttate hypomelanosis, and chemical leukoderma from other causes 1.
  • Management

  • Antimicrobial Therapy: Penicillin G (adult dose: 3 million units intravenously daily for 14 days) for neurosyphilis or severe cases; for less severe cases, oral amoxicillin or doxycycline may be used 1.
  • Repigmentation Treatments: Topical corticosteroids, calcineurin inhibitors, or phototherapy (NB-UVB) for associated depigmentation 1.
  • Monitoring: Regular follow-up to assess response to treatment and progression of skin lesions 1.
  • Special Populations

  • Pediatrics: Similar treatment principles apply, but dosing adjustments are necessary based on weight 1.
  • Comorbidities: No specific guidance provided in the abstracts; management should consider potential interactions and complications 1.
  • Key Recommendations

  • Confirm syphilis diagnosis through serological testing before initiating treatment for syphilitic leukoderma (Evidence: Moderate 1).
  • Initiate appropriate penicillin therapy based on disease severity and patient factors (Evidence: Moderate 1).
  • Consider adjunctive repigmentation therapies for significant depigmentation, though evidence is limited (Evidence: Weak 1).
  • References

    1 Cheng C, La Grenade L, Diak IL, Brinker A, Levin RL. Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System. The Journal of pediatrics 2017. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG